Long Wharf Theatre in New Haven has appointed Tim Yergeau as its new director of marketing and communications following a nationwide search.
Yergeau, a New Haven resident, will help publicize the theater’s programming as it launches its 2022-2023 season.
Yergeau has a background in marketing and communications for organizations such as Planned Parenthood of Southern New England, the New Haven Free Public Library Foundation, Civic Mind, the Greater Hartford Arts Council and Hartford Stage.
Yergeau has helped generate millions of dollars in revenue for the arts and community causes, according to an announcement.
Kit Ingui, managing director of Long Wharf Theatre, said, “Tim brings with him unparalleled experience in his field, which will be invaluable as we continue to tell our story in new ways to audiences.”
The theater is embarking on a new itinerant model, with productions to take place around the region.
*****
DiamiR Biosciences names new CEO
DiamiR, a New Haven-based developer of blood-based diagnostic tests for brain health and other diseases, recently appointed Alidad Mireskandari as the company’s new chief executive officer.
Mireskandari has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization.
Mireskandari most recently served as chief development officer of Interpace Biosciences, and prior to that as president and CEO of JS Genetics.
*****
Rallybio selects new board member
Rallybio Corporation, a New Haven-based, clinical-stage biotechnology company, recently appointed Dr. Wendy K. Chung to its board of directors.
Rallybio is working to develop treatments for severe and rare diseases, including in the areas of hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders.
Chung is a board-certified clinical and molecular geneticist with more than 20 years of experience in human genetic research.
“As a clinician, I have seen firsthand the significant unmet need for transformative therapies for patients with severe and rare diseases,” Chung said. “I look forward to utilizing my scientific background and prior experience to contribute to the board and the work of the Rallybio team.”
